Factors associated with dose adjustment for the bortezomib, lenalidomide, dexamethasone regimen among patients with newly diagnosed multiple myeloma.

被引：0
|
作者：
Ran, Tao
Medhekar, Rohan
Fu, Alex Z.
Patel, Sharmila
Kaila, Shuchita
机构：
[1] Janssen Sci Affairs LLC, Horsham, PA USA
[2] Georgetown Univ, Med Ctr, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8039
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
    Kazuhito Suzuki
    Nobuhiro Tsukada
    Noriko Nishimura
    Yasuyuki Nagata
    Kiyoshi Okazuka
    Yuko Mishima
    Masahiro Yokoyama
    Kaichi Nishiwaki
    Tadao Ishida
    Shingo Yano
    Yasuhito Terui
    Kenshi Suzuki
    International Journal of Hematology, 2020, 111 : 103 - 111
  • [42] Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study
    Chen, Runzhe
    Zhang, Xiaoping
    Gao, Chong
    Luan, Chengxin
    Wang, Yujie
    Chen, Baoan
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 373 - 380
  • [43] The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
    Okazuka, Kiyoshi
    Ishida, Tadao
    Nashimoto, Junichiro
    Uto, Yui
    Sato, Kota
    Miyazaki, Kanji
    Ogura, Mizuki
    Yoshiki, Yumiko
    Abe, Yu
    Tsukada, Nobuhiro
    Suzuki, Kenshi
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (02) : 110 - 115
  • [44] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
    Suzuki, Kazuhito
    Tsukada, Nobuhiro
    Nishimura, Noriko
    Nagata, Yasuyuki
    Okazuka, Kiyoshi
    Mishima, Yuko
    Yokoyama, Masahiro
    Nishiwaki, Kaichi
    Ishida, Tadao
    Yano, Shingo
    Terui, Yasuhito
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (01) : 103 - 111
  • [45] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
    Voorhees, Peter M.
    Kaufman, Jonathan L.
    Laubach, Jacob
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne A.
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Murphy, Sean
    Lutska, Yana
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    de Boer, Carla
    Hoehn, Daniela
    Lin, Thomas S.
    Richardson, Paul G.
    BLOOD, 2020, 136 (08) : 936 - 945
  • [46] Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment
    Jian, Yuan
    Chang, Long
    Shi, Ming-Xia
    Sun, Ying
    Chu, Xiao-Xia
    Xue, Hua
    Huang, Wen-Rong
    Shen, Xu-Liang
    Ma, Jie
    Jia, Guo-Rong
    Feng, Ya-Qing
    Xi, Zhen-Fang
    Zhao, Yan-Hong
    Ma, Yan-Ping
    Xiao, Jing
    Ma, Guang-Yu
    Wang, Qing-Ming
    Bao, Li
    Dong, Yu-Jun
    Zhou, He-Bing
    Sun, Chun-Yan
    Su, Guo-Hong
    Yan, Yan
    Qimuge, Sai-Yin
    Su, Li-Ping
    Sun, Jing-Nan
    Tian, Wei-Wei
    Sun, Xiu-Li
    Ing, Hong-Mei
    Gao, Da
    Chen, Wen-Ming
    Li, Jian
    Gao, Wen
    BLOOD ADVANCES, 2023, 7 (24) : 7581 - 7584
  • [47] Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
    Zafar, Mir Sadaqat Hassan
    Khan, Afaq Ahmed
    Aggarwal, Shyam
    Bhargava, Manorama
    SOUTH ASIAN JOURNAL OF CANCER, 2018, 7 (01) : 58 - 60
  • [48] A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
    Figueiredo, Amarilis
    Atkins, Harold
    Mallick, Ranjeeta
    Kekre, Natasha
    Kew, Andrea
    McCurdy, Arleigh
    BLOOD, 2016, 128 (22)
  • [49] A comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM)
    Khan, M. L.
    Reeder, C. B.
    Kumar, S.
    Lacy, M.
    Reece, D. E.
    Laumann, K. M.
    Mikhael, J.
    Fonseca, R.
    Rajkumar, V.
    Stewart, A. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Real World Treatment Outcomes and Cost Among Newly-Diagnosed Multiple Myeloma Patients Treated with Bortezomib and Dexamethasone in Combination with Cyclophosphamide or Lenalidomide
    Xie, Lin
    Parikh, Kejal
    Abouzaid, Safiya
    Pandya, Shivani
    Baser, Onur
    Patel, Manali I.
    BLOOD, 2016, 128 (22)
12345